Tag: $Novo Nordisk

Novo Nordisk (NVO) traded higher in the U.S. after the U.K.’s healthcare regulator approved a higher dose of Novo’s blockbuster weight-loss drug, Wegovy.

Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity treatment in the U.S.

Novo Nordisk shares received a much-needed end of the year boost as the Wegovy maker became the first drugmaker to secure approval of a GLP-1 pill for weight loss, in what one analyst called a “redemption for the investors” after the stock’s worst year ever.

Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.

Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry.

Shares of Novo Nordisk on Monday fell to a four-year low after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal.

Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to make the treatments more accessible.

Shares of Metsera, fell nearly 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer, to end a fierce bidding war between the pharma giant and Danish rival Novo Nordisk.

Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market.

Novo Nordisk on Wednesday flagged promising late-stage trial results for its new Cagrilinitide obesity treatment, as the Danish pharmaceutical giant seeks a next-generation alternative to its blockbuster Wegovy weight-loss drug.

Novo Nordisk A/S (NYSE:NVO) stock rose 2.8% in Monday’s premarket trading after the European Medicines Agency approved an update to the Rybelsus label to include cardiovascular benefits for patients with type 2 diabetes.

Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut around 9,000 roles, or roughly 11.5% of its global workforce.

Novo Nordisk’s (NOVO.B) Wegovy cut the risk of heart attacks, stroke and death by more than Eli Lilly’s (LLY) weight-loss drug Zepbound, a new study found.

Denmark on Friday slashed its annual growth forecast to 1.4% from 3%, in large part due to weaker expectations for pharmaceutical giant Novo Nordisk.

Wegovy-maker Novo Nordisk (NOVOb.CO), has implemented a global hiring freeze covering job roles that are not critical for its business, the company said on Wednesday.

Shares of  Novo Nordisk climbed almost 5% Monday after the company’s blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease.

Novo Nordisk(NVO) vowed to cut costs Wednesday amid intensifying competition and a cratering stock price as it reported second-quarter earnings.

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its blockbuster Wegovy obesity drug in the key U.S. market.

 Eli Lilly (LLY.N), said on Thursday that India’s drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk’s recently launched Wegovy.

Shares in Novo Nordisk (NYSE:NVO) fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly (NYSE:LLY)’s pipeline.